PIMSH17 – Oncology: Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (inverse measure)

Measure Title:Oncology: Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (inverse measure)

Measure Description: Percentage of patients with cancer (solid tumors only) receiving any white cell growth factors with during the first cycle of low-risk chemotherapy.

Denominator: Total number of patients with cancer (solid tumors only) receiving their first cycle of low-risk chemotherapy within the measurement period AND patient encounter during the measurement period.

Numerator: Patients ordered GCSF within 7 days following receipt of chemotherapy for metastatic colorectal cancer

Denominator Exclusions: Patients on clinical trial at the time of treatment

Denominator Exceptions: None

Numerator Exclusions: None

Published Specialty: Hematology & Oncology

High Priority Measure: Yes

Measure Type: Efficiency

Include Telehealth: Yes

Inverse Measure: Yes

Proportional Measure: Yes

Continuous Variable Measure: No

Ratio Measure: No

Score Range: N/A

Number of Performance Rates: 1

Performance Rate Description: N/A

Risk Adjusted Status: No

MIPS Reporting Options: MVP, Traditional MIPS

Care Setting: Ambulatory Care: Clinician Office/Clinic

Clinical Recommendation Statement: This measure is endorsed by the US Oncology Network of Physicians. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Updates (2015). ASCO guidelines recommend using white cell stimulating factors when the risk of febrile neutropenia, secondary to a recommended chemotherapy regimen, is approximately 20 percent and equally effective treatment programs that do not require white cell stimulating factors are unavailable.

Measure Rationale: